The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward - Université de Lorraine Access content directly
Journal Articles Kidney International Year : 2019

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward

Abstract

The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639).Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Fichier principal
Vignette du fichier
S0085253819300067.pdf (4.74 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02510924 , version 1 (22-10-2021)

Licence

Attribution - NonCommercial

Identifiers

Cite

Patrick Rossignol, Luc Frimat, Faiez Zannad. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney International, 2019, 95 (4), pp.747-749. ⟨10.1016/j.kint.2018.12.006⟩. ⟨hal-02510924⟩
43 View
69 Download

Altmetric

Share

Gmail Facebook X LinkedIn More